Evidence Hub

Yishen Qianggu Mixture formulation suppresses osteometabolic inflammation by modulating the IL-17/NF-κB/MAPK signaling axis

Zhao J, Peng GG, Xiao D, Fu CJ, Chen HZ, Luo SJ, Wu HQ, Huang M

Journal of ethnopharmacology, 2026

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Yishen Qianggu Mixture (YSQGM) is a clinical empirical formula derived from Traditional Chinese Medicine (TCM) theory of "benefiting the kidney and strengthening bones," traditionally used to treat postmenopausal osteoporosis (PMOP) associated with kidney yang deficiency. Preliminary studies have shown that YSQGM improves bone mineral density (BMD), yet its integration of traditional efficacy with modern anti-inflammatory and bone metabolism-regulating mechanisms remains unclear.

AIM OF THE STUDY: To elucidate YSQGM's anti-inflammatory effects and mechanisms on PMOP, with emphasis on verifying its inflammation-regulating role via multi-omics analysis and experimental validation.

METHODS: An ovariectomy (OVX)-induced PMOP model was established in 36 Sprague-Dawley (SD) rats randomly assigned to six groups. Rats received YSQGM or alendronate by gavage for 8 weeks. BMD and trabecular microarchitecture were assessed by micro-computed tomography (Micro-CT), while serum bone turnover markers and inflammatory cytokines were measured by ELISA. Untargeted metabolomics and network pharmacology were integrated to identify differential metabolites and construct protein-protein interaction networks. Key targets were further examined by molecular docking, molecular dynamics (MD) simulations, and in vivo/in vitro validation.

RESULTS: Medium and high doses of YSQGM significantly increased BMD, concomitantly decreased markers of bone formation and bone…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free